{"disease":{"id":"thromboangiitis-obliterans","name":"Thromboangiitis obliterans","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"limaprost","indication_name":"Thromboangiitis obliterans","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opalmon","generic_name":"LIMAPROST","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP1 subtype","drug_class":"limaprost","quality_score":17,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07023965","title":"Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":542,"lead_sponsor_name":"Beijing Northland Biotech. Co., Ltd.","has_results":false},{"nct_id":"NCT02501018","title":"Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Lisata Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04914247","title":"Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Actelion","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}